Filter By Category
Archives
Share on -
ALIRINETIDE
Generic Name: ALIRINETIDE
ABSTRACT -
Alirinetide, also known as GM604 or GM6, is an investigational synthetic peptide consisting of the amino-acid sequence phenylalanine-serine-arginine-tyrosine-alanine-arginine. It has been studied as a neuroprotective or neurotrophic-modulating candidate in neurologic disorders such as amyotrophic lateral sclerosis. It is not an approved routine therapy and should be used only under clinical-trial or specialist medical supervision.
DOSAGE -
- Alirinetide is investigational and does not have a universally established approved dosage regimen.
- Clinical studies have used protocol-defined parenteral administration schedules rather than routine outpatient dosing.
- Dose, route, infusion or injection procedure, treatment duration, laboratory monitoring, and neurologic assessments must follow the study protocol.
- It should not be used for self-medication or substituted for approved neurologic therapies.
SIDE EFFECTS–
- Reported or potential side effects may include:
- Injection-site reaction
- Headache
- Dizziness
- Fatigue
- Nausea
- Flushing
- Fever or chills
- Muscle aches
- Laboratory abnormalities
- Allergic or hypersensitivity reactions
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Skin rash
- Itching
- Hives
- Swelling of face, lips, tongue, or throat
- Difficulty breathing
- Wheezing
- Severe dizziness
- Rapid heartbeat
- Chest tightness
- Anaphylaxis
- Severe hypersensitivity reactions
DRUG INTERACTIONS–
- The interaction profile may include or require caution with:
- Other investigational neurologic medicines
- Immunomodulating or biologic therapies
- Anticoagulants or antiplatelet medicines if injections or infusions are used
- Medicines that may worsen dizziness or sedation
- Supplements or alternative therapies used for neurologic disease
- Any therapy restricted by the clinical study protocol
- Patients should inform healthcare providers about all prescription medicines, non-prescription medicines, herbal products, and supplements being used.
PREAUTIONS–
- Use only in a clinical-trial or specialist neurologic setting with appropriate monitoring.
- Document baseline neurologic status, respiratory status when relevant, swallowing status, and concomitant medicines.
- Monitor for infusion or injection reactions, hypersensitivity, neurologic worsening, and laboratory abnormalities.
- Use caution in patients with severe infection, unstable cardiopulmonary disease, bleeding risk, or multiple serious comorbidities.
- Pregnancy, breastfeeding, and pediatric safety have not been established.
WARNINGS –
- Alirinetide is investigational; safety, efficacy, optimal dose, and routine clinical role have not been fully established.
- Neurologic diseases such as ALS require specialist management with approved supportive and disease-directed care where appropriate.
- Severe allergic reaction, breathing difficulty, fainting, rapidly worsening weakness, or serious infusion reaction requires urgent care.
- Treatment should be stopped and evaluated if severe adverse reaction or clinical deterioration is suspected.
- Keep out of reach of children.
Share on -
. Developed by